Home » Topics » BioWorld Science

BioWorld Science
RSS

Navitor presents data from phase I program of NV-5138

Sep. 13, 2019

GT Biopharma initiates enrollment in first-in-human study of GTB-3550

Sep. 13, 2019

Wharton's jelly-derived mesenchymal stem cells evaluated in chronic ischemic heart failure

Sep. 13, 2019

Bug likes bleach

Sep. 13, 2019

In vivo research suggests E-cadherin drives metastasis

Sep. 13, 2019

Moderna offers phase I data from chikungunya and CMV programs

Sep. 12, 2019

Prevail Therapeutics advances development of PR-001 for Parkinson's and Gaucher's diseases

Sep. 12, 2019

Adverum reports 24-week cohort 1 data from phase I study of ADVM-022 in wet AMD

Sep. 12, 2019

Tubulis enters collaboration with Glycotope for development of novel ADC therapy

Sep. 12, 2019

Ocrelizumab in RRMS: CASTING study phase III results presented

Sep. 12, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...